{"issuance_frequency":"","notes_translated":{"fr":"Ce recueil de points à considérer présente une approche réglementaire pour la mise à jour des vaccins autorisés contre les coronavirus si des mutations devaient à tout moment les rendre moins efficaces en raison d'une réactivité croisée insuffisante.","en":"This Points to Consider document lays out a regulatory approach for updating authorised coronavirus vaccines should mutations at any time make them less efficacious due to insufficient cross-reactivity."},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"9f355e93-02cd-4199-8dab-28ad158a79b4","metadata_created":"2021-06-30T17:46:16.006585","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-06-30T17:46:16.006591","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-06-30","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["COVID-19","Coronavirus","pandémie","vaccin","Consortium ACCESS","changements dans les vaccins COVID-19 autorisés","réglementation","réglementation","variantes","Collaboration internationale"],"en":["COVID-19","Coronavirus","pandemic","vaccine","ACCESS Consortium","changes in authorised COVID-19 vaccines","regulations","regulatory","variants","International collaberation"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Le Consortium ACCESS : points à considérer concernant la modification des souches dans les vaccins autorisés contre la COVID-19, dans le cadre de l’actuelle pandémie de SRAS-CoV-2","en":"ACCESS Consortium: Points to consider for strain changes in authorised COVID-19 vaccines in an ongoing SARS-CoV2 pandemic"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"9f355e93-02cd-4199-8dab-28ad158a79b4","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"35cb4934-0d72-4c4f-9281-8295d0fd08af","related_relationship":"","name_translated":{"fr":"Le Consortium ACCESS : points à considérer concernant la modification des souches dans les vaccins autorisés contre la COVID-19, dans le cadre de l’actuelle pandémie de SRAS-CoV-2","en":"ACCESS Consortium: Points to consider for strain changes in authorised COVID-19 vaccines in an ongoing SARS-CoV2 pandemic"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"ACCESS Consortium: Points to consider for strain changes in authorised COVID-19 vaccines in an ongoing SARS-CoV2 pandemic","language":["en"],"created":"2021-06-30T17:46:16.110877","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/access-guidance-vaccines-strain-changes.html","last_modified":null,"position":0,"revision_id":"ce2e7f31-6e15-4228-8dfa-248f16801dac","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"9f355e93-02cd-4199-8dab-28ad158a79b4","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"1dca02ff-880a-4c5f-8755-0fb767c607e9","related_relationship":"","name_translated":{"fr":"Le Consortium ACCESS : points à considérer concernant la modification des souches dans les vaccins autorisés contre la COVID-19, dans le cadre de l’actuelle pandémie de SRAS-CoV-2","en":"ACCESS Consortium: Points to consider for strain changes in authorised COVID-19 vaccines in an ongoing SARS-CoV2 pandemic"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"ACCESS Consortium: Points to consider for strain changes in authorised COVID-19 vaccines in an ongoing SARS-CoV2 pandemic","language":["fr"],"created":"2021-06-30T17:46:16.110884","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/covid19-industrie/medicaments-vaccins-traitements/access-orientation-modification-souches-vaccins.html","last_modified":null,"position":1,"revision_id":"ce2e7f31-6e15-4228-8dfa-248f16801dac","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2021-03-03 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"9f355e93-02cd-4199-8dab-28ad158a79b4","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"This Points to Consider document lays out a regulatory approach for updating authorised coronavirus vaccines should mutations at any time make them less efficacious due to insufficient cross-reactivity.","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"ACCESS Consortium: Points to consider for strain changes in authorised COVID-19 vaccines in an ongoing SARS-CoV2 pandemic","revision_id":"ce2e7f31-6e15-4228-8dfa-248f16801dac"}